Arcus Biosciences (RCUS) – Analysts’ Weekly Ratings Updates

Arcus Biosciences (NYSE: RCUS) recently received a number of ratings updates from brokerages and research firms:

• 11/5/2026 – Arcus Biosciences had its price target raised by Leerink Partners from $46.00 to $49.00. They now have an “outperform” rating on the stock.
• 11/5/2026 – Arcus Biosciences had its price target lowered by Truist Financial from $41.00 to $40.00. They now have a “buy” rating on the stock.
• 11/5/2026 – Arcus Biosciences had its price target lowered by Wedbush from $49.00 to $45.00. They now have an “outperform” rating on the stock.
• 10/24/2026 – Arcus Biosciences was downgraded by Wall Street Zen from “hold” to “sell”.
• 10/21/2026 – Arcus Biosciences had its price target raised by Citigroup from $45.00 to $50.00. They now have a “buy” rating on the stock.
• 10/21/2026 – Arcus Biosciences had its price target raised by Truist Financial from $40.00 to $41.00. They now have a “buy” rating on the stock.
• 10/21/2026 – Arcus Biosciences had its price target raised by Wedbush from $43.00 to $49.00. They now have an “outperform” rating on the stock.
• 10/16/2026 – Arcus Biosciences is now covered by William Blair. They set an “outperform” rating on the stock.
• 10/15/2026 – Arcus Biosciences had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/14/2026 – Arcus Biosciences is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $41.00 price target on the stock.
• 10/3/2026 – Arcus Biosciences was upgraded by Wall Street Zen from “sell” to “hold”.
• 9/30/2026 – Arcus Biosciences had its “outperform” rating reaffirmed by Wedbush. They now have a $43.00 price target on the stock.
• 9/16/2026 – Arcus Biosciences is now covered by TD Cowen. They set a “buy” rating on the stock.
• 9/11/2026 – Arcus Biosciences had its “overweight” rating reaffirmed by Cantor Fitzgerald.

Arcus Biosciences Stock Performance

Shares of Arcus Biosciences stock traded up $0.69 on Monday, reaching $18.97. 484,453 shares of the stock were exchanged, compared to its average volume of 1,419,946. The company has a quick ratio of 3.34, a current ratio of 3.34 and a debt-to-equity ratio of 0.28. Arcus Biosciences, Inc. has a twelve month low of $17.43 and a twelve month high of $31.74. The firm has a market capitalization of $2.73 billion, a price-to-earnings ratio of -5.23 and a beta of 1.04. The business has a 50 day moving average price of $23.74 and a two-hundred day moving average price of $24.54.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Wednesday, November 4th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.11). The business had revenue of $9.00 million for the quarter, compared to analysts’ expectations of $7.58 million. Arcus Biosciences had a negative return on equity of 91.65% and a negative net margin of 453.00%. The business’s quarterly revenue was down 65.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.27) earnings per share. Analysts anticipate that Arcus Biosciences, Inc. will post -3.57 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Arcus Biosciences news, CAO Alexander Azoy sold 2,827 shares of the stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $30.00, for a total transaction of $84,810.00. Following the sale, the chief accounting officer directly owned 39,581 shares of the company’s stock, valued at approximately $1,187,430. This trade represents a 6.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 7.60% of the company’s stock.

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Founded in 2015 and headquartered in Hayward, California, the company researches therapies that target immune pathways and other processes involved in tumor growth.

Its pipeline consists of investigational medicines, including antibody and small-molecule candidates designed to be used alone or in combination. Arcus’s research has focused on areas such as checkpoint inhibition and the adenosine pathway; its candidates are under clinical development and are not established treatments.

Arcus works with Gilead Sciences on the development of oncology medicines, extending its work through a major biopharmaceutical collaboration.